What conditions is Quizartinib mainly used to treat?

Quizartinib (Quizartinib), sold under the brand name Vanflyta, is a targeted anti-cancer drug for acute myeloid leukemia (AML). It is a small molecule receptor tyrosine kinase inhibitor, and its unique molecular target is FLT3, also known as CD135, which is a common proto-oncogene in acute myeloid leukemia. FLT3 mutations, especially internal tandem duplication (ITD) mutations of FLT3, are one of the most common molecular abnormalities in AML, and the presence of such mutations often predicts a poor prognosis for patients.

Quizatinib effectively blocks the cell signaling pathway driven by FLT3-ITD mutations by inhibiting the activity of FLT3 kinase, thereby inhibiting the proliferation and survival of leukemia cells. This mechanism of action makes quizartinib an effective drug for the treatment of patients with FLT3-ITD-positive AML.

In clinical practice, quizartinib is usually used in adult AML patients who have received at least one treatment and have failed to respond. It can be used not only as a monotherapy but also in combination with standard chemotherapy drugs such as cytarabine and anthracyclines to enhance the effectiveness of the treatment. The recommended dosage and use of quizartinib will be based on the patient's specific condition and tolerance, and the patient's response and possible side effects need to be closely monitored during use.

It is worth noting that the approval of quizartinib was based on its significant efficacy and safety demonstrated in multiple clinical trials. These trials have shown that quizartinib can significantly prolong the progression-free survival and overall survival of patients with FLT3-ITD-positive AML, and bring complete remission or partial remission to some patients. At the same time, the use of quizartinib also requires attention to possible side effects such as cardiotoxic reactions. Therefore, it is necessary to strictly follow medical instructions and conduct regular electrocardiogram monitoring during use.

In general, quizartinib, as a targeted therapy for FLT3-ITD mutation-positive AML patients, provides new treatment options and hope for such patients.

xa0

Reference: https://en.wikipedia.org/wiki/Quizartinib